Effects of bortezomib-based therapy on hemostasis system and circulating microparticles in multiple myeloma patients |
| |
| Authors: | DIAO Xiang-wen LI Juan LIU Jun-ru HUANG Bei-hui LI Ying |
| |
| Institution: | Department of Hematology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, China. |
| |
| Abstract: | AIM：To investigate the changes of hemostasis, thrombosis and total microparticles (TMPs) in multiple myeloma (MM) patients receiving bortezomib-based induction therapy (bortezomib+adriamycin+dexamethasone, PAD). METHODS：The levels of TMPs were detected by flow cytometry in 38 newly diagnosed MM patients and 30 healthy people. The changes of the platelet, coagulation, anticoagulation, fibrinolytic activation and TMPs in the MM patients before and after PAD teatment were also studied.RESULTS：Before treatment, the values of FVIII:C and vWF:Rco in MM patient were elevated ［(152.89±31.14)% and (165.69±38.43)%］, the activation of platelet aggregation was inhibited ［(63.76±21.36)%］, and the PAI level increased ［3.98(1.63)U/mL］. Compared with the healthy people, higher concentration of TMPs was observed in MM patients ［(640.65±214.22)/μL vs (134.29±63.09)/μL, P<0.01］, and the level of TMPs was positively correlated with serum β2-MG (r=0.672, P<0.01).After PAD therapy, platelet aggregation activation was restored ［(77.83±15.62)%, P=0.01］, and PAI level decreased ［0.88(1.38)U/mL, P<0.01］. The level of TMPs also decreased, after 3 cycles of PAD, to the value of (184.25±93.35)/μL. CONCLUSION：MM patients were characterized by impaired platelet, coagulation and fibrinolysis functions, and increased level of TMPs. PAD restored platelet function, decreased the levels of PAI and TMPs, which might partially explain the low incidence of thrombosis in the MM patients receiving bortezomib-based treatment. |
| |
| Keywords: | Multiple myeloma Bortezomib Microparticles |
|
| 点击此处可从《园艺学报》浏览原始摘要信息 |
| 点击此处可从《园艺学报》下载免费的PDF全文 |
|
